Yes, the effectiveness of the COVID-19 vaccine for multiple myeloma (MM) patients has been studied. Here are some key points:

- Additional Dose Benefits: Research shows that more than half of those with B-cell blood cancers, including multiple myeloma, who did not produce COVID-19 antibodies after the first two doses, did Show Full Answer

Yes, the effectiveness of the COVID-19 vaccine for multiple myeloma (MM) patients has been studied. Here are some key points:

- Additional Dose Benefits: Research shows that more than half of those with B-cell blood cancers, including multiple myeloma, who did not produce COVID-19 antibodies after the first two doses, did produce antibodies after a third dose. Those who did produce antibodies after the first two doses had an improved antibody response after the third dose.

- Recommendations: The Leukemia & Lymphoma Society recommends that people with blood cancer who are fully vaccinated get an additional dose of the vaccine.

- Eligibility for Boosters: People with multiple myeloma who are considered immunocompromised may be eligible for a third dose of the Pfizer or Moderna vaccines at least 28 days following their second dose. If not considered immunocompromised, they may be eligible for a booster six months after the second dose, depending on age and other health conditions.

- Mix and Match Boosters: Health agencies have approved "mix and match" boosters, meaning a person may receive initial doses of one type of COVID-19 vaccine and a booster of another.

For the most accurate and personalized advice, it's important to consult with a healthcare provider.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Are People With Myeloma Eligible for Moderna and Johnson & Johnson Booster Shots? | MyMyelomaTeam

Myeloma Awareness: How To Get Involved | MyMyelomaTeam